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Abstract 
Body dysmorphic disorder (BDD) is a chronic and disabling psychiatric disorder 
unlikely to remit without treatment. A systematic review and meta-analysis of randomized 
controlled trials (RCTs) of cognitive-behavioral therapy (CBT) for BDD was conducted, 
including published and unpublished trials to 26
th
 November 2015. Primary outcomes were 
validated BDD measures; secondary outcomes included depression and insight. Meta-
regressions were conducted to examine potential effects of variables on the primary outcome, 
including socio-demographic variables, comorbidity, symptom severity/duration, 
concomitant medication, treatment duration, and methodological quality of the RCTs. Seven 
RCTs (N = 299) met inclusion criteria. CBT was superior to waitlist or credible 
psychological placebo in reducing BDD (7 studies; delta = -1.22, 95% CI = -1.66 to -0.79) 
and depression symptoms (5 studies; delta = -0.49, 95% CI = -0.76 to -0.22). CBT was 
associated with improvements in insight/delusionality (4 studies; delta=-0.56, 95% CI=-0.93 
to -0.19). Improvement in BDD was maintained after 2-4 months follow-up (3 studies; 
delta=-0.89, 95% CI =-1.24 to -0.54). Meta-regression analyses did not reveal any significant 
predictors of outcome. CBT is an efficacious treatment for BDD but there is substantial room 
for improvement. The specificity and long-term effects of CBT for BDD require further 
evaluation using credible control conditions. Additional trials comparing CBT with 
pharmacological therapies, as well as their combination, are warranted. Tele-care options, 
such as Internet-based CBT, hold great promise to increase access to evidence-based 
treatment for a majority of patients who need it, and should be evaluated further.  
 
Keywords: Body Dysmorphic Disorder; Cognitive-Behavioral Therapy; Treatment; Meta-
analysis; Systematic Review; Randomized Controlled Trial.  
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Introduction 
Body dysmorphic disorder (BDD) is characterized by a persistent preoccupation with 
perceived defects or flaws in one‟s appearance, which are unnoticeable to others (American 
Psychiatric Association, 2013). This preoccupation leads to time-consuming rituals (e.g., 
mirror checking) and marked avoidance, which cause significant distress and impairment 
(Didie, Menard, Stern, & Phillips, 2008), and results in poor quality of life (Phillips, 2000). 
BDD is also linked with strikingly high suicidal behavior (Phillips, Menard, Pagano, Fay, & 
Stout, 2006a; Phillips, 2005; Phillips et al., 2005). Approximately one third of patients lack 
insight into their difficulties, which they attribute to objective physical flaws rather than 
being emotional in origin (Phillips et al., 2006b). BDD is relatively common, with prevalence 
estimates ranging from 1.7% to 2.4% (Buhlmann et al., 2010; Koran, Abujaoude, Large, & 
Serpe, 2008; Rief, Buhlmann, Wilhelm, Borkenhagen, & Brähler, 2006). The onset typically 
occurs during adolescence, with earlier onsets associated with a more insidious form of 
illness, a higher frequency of suicide attempts, and greater comorbidity (Bjornsson et al., 
2013). High comorbidity with major depressive disorder, social anxiety disorder, and 
obsessive-compulsive disorder (OCD), amongst others, is frequently reported (Gunstad & 
Phillips, 2003). 
BDD is unlikely to resolve without an evidence-based intervention (Phillips, Menard, 
Quinn, Didie, & Stout, 2013). Two principal forms of treatment are thought to be efficacious 
for BDD, namely serotonin reuptake inhibitors (SRIs) and cognitive-behavior therapy (CBT) 
adapted for BDD and including exposure with response prevention (ERP) techniques. 
Regarding pharmacotherapy, a limited number of double blind placebo-controlled trials have 
shown that clomipramine (relative to desimipramine; Hollander et al., 1999) and fluoxetine 
(relative to placebo; Phillips, Albertini, & Rasmussen, 2002) are efficacious in BDD, while 
SRI non-responders do not seem to benefit from augmentation with low doses of 
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antipsychotics (Phillips, 2005). A further relapse prevention trial has recently shown that, 
amongst responders to escitalopram, continuation of escitalopram was associated with lower 
relapse rates and longer time to relapse, compared to patients who were switched to placebo 
(Phillips et al., 2016).   
Regarding CBT, a previous meta-analysis (Ipser, Sander, & Stein, 2009) identified 
three randomized controlled trials (RCT) –  with available data for analyses from two studies 
(combined n = 36) – and concluded that CBT significantly reduced BDD symptoms, relative 
to waitlist/no treatment conditions (Weighted Mean Difference = -44.96, 95% CI -54.43 – -
35.49). Thus, the evidence base for CBT, upon which international guidelines like the 
National Institute for Health and Clinical Excellence (NICE) (National Institute for Health 
and Clinical Excellence, 2006) rely, was relatively weak. Since the publication of that meta-
analysis, several additional RCTs of CBT for BDD have been conducted, motivating the 
current study.  
The primary aim was to investigate the efficacy of CBT for BDD through a 
systematic review and meta-analysis of all published and unpublished RCTs for individuals 
with BDD of all ages, with primary outcomes of treatment response determined using 
validated measures of BDD. As a secondary aim, the effect of CBT on depressive symptoms 
and insight in patients with BDD was investigated. The planned analyses also included meta-
regression to examine the potential effect of symptom severity, number of CBT sessions and 
therapy hours, comorbidities, insight, use of medication, previous cosmetic procedures, 
gender, age, and duration of the disorder on the outcomes studied.  
 
Methods 
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The review was conducted using the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) checklist and protocol outlined by the PRISMA 
Group (Moher, Liberati, Tetzlaff, & Altman, 2009). 
 
Protocol and Registration 
The protocol of this review was registered with the International Prospective Register 
for Systematic Reviews (PROSPERO), number CRD42015025513, available 
from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015025513. 
Eligibility Criteria 
Studies were eligible for inclusion if they: A) Included patients with a diagnosis of 
BDD established using the Diagnostic and Statistical Manual of Mental Disorders (DSM) in 
any of its editions (DSM-III-R; (American Psychiatric Association, 1987); DSM-IV; 
(American Psychaitric Association, 1994); DSM-IV-TR; (American Psychiatric Association, 
2000);  DSM-5; (American Psychiatric Association, 2013), or the International Classification 
of Diseases (ICD) in its 9
th
 or 10
th
 editions (World Health Organisation, 1975, 1999); B) 
reported results of an RCT evaluating the efficacy of CBT (in all its varieties and formats) 
against a waitlist/no treatment, treatment as usual, other psychotherapies, or a credible 
psychological placebo; and C) contained sufficient data for analyses. No language or age 
restrictions were set.  
 
Information Sources 
Two of the authors (AH and LFC) conducted an independent systematic two-step 
literature search to identify relevant articles. First, EMBASE, MEDLINE®, and PsycInfo 
were searched to detect published and unpublished studies on CBT for individuals with BDD. 
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Databases were searched up to November 26
th
 2015. Second, manual searches of the 
reference lists of previous reviews and the retrieved articles were performed. Additionally, 
research teams in the field were contacted for unpublished RCTs, as were the contacts for the 
registered incomplete trials reported in the previous review (Ipser et al., 2009). 
 
Search  
The search was performed in the above-mentioned databases using the Ovid® search 
engine. No limits were set. The search algorithm included the terms BDD and related variants 
(body dysmorphic disorder OR dysmorphophobia OR dysmorphia), CBT and related variants 
(cognitive behavio* therapy OR behavio* therapy OR cognitive therapy OR therapy OR 
treatment), and RCT and related variants (randomi* controlled trial OR controlled clinical 
trial OR random allocation OR double-blind method OR single-blind method OR clinical 
trial OR comparative study). Results from the three blocks were combined and duplicates 
removed subsequently.  
 
Study Selection 
Abstracts were initially screened to ascertain whether the reported study met the 
eligibility criteria described above. If eligibility criteria were met, the full text article was 
retrieved and screened for the presence of sufficient data for analysis. Where this was not the 
case, the corresponding author of the article was contacted and data were requested. 
The data extracted for the meta-analysis were taken from the controlled phase of the 
RCTs, comparing CBT with a waitlist or other control condition both during the active phase 
of the treatment and any follow-up points when available. Thus, if additional CBT sessions 
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were offered after the primary endpoints, or patients in the waitlist/control groups were 
offered to crossover to CBT after the primary endpoint, these were not analyzed. 
 
Data Collection Process 
Data extraction and quality assessment were independently performed by two of the 
authors (AH and LFC). Disagreement between the two authors concerning the extracted data 
was resolved via discussion until a consensus was reached. Any uncertainty regarding the 
extraction of data from a particular study was resolved via contact with the study authors.  
 
Data Items  
For each article, pre-treatment, post-treatment, and follow-up (when available) means, 
standard deviations, effect sizes of the difference in severity decrease between CBT and the 
waitlist/control group were recorded for both primary and secondary outcomes. The primary 
outcome measure was improvement in BDD symptoms, measured by either the Yale-Brown 
Obsessive Compulsive Scale for Body Dysmorphic Disorder (BDD-YBOCS; Phillips, 
Hollander, Rasmussen, & Aronowitz, 1997), or the Body Dysmorphic Disorder Examination 
(BDDE; Rosen & Reiter, 1996). The secondary outcomes were the improvement in 
depressive symptoms, measured by either the Montgomery-Åsberg Depression Rating Scale 
(MADRS; Montgomery & Asberg, 1979), the Beck Depression Inventory (BDI; Beck, Ward, 
& Mendelson, 1961), or the Hospital Anxiety and Depression Scale (HADS; Zigmond & 
Snaith, 1983), and the improvement in insight, measured by the Brown Assessment of Beliefs 
Scale (BABS; Eisen et al., 1998), or the insight item of the BDD-YBOCS; Phillips et al., 
1997). 
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Additionally, the following variables were recorded: year of publication, sample size, 
participant‟s gender, age, illness duration, use of psychoactive medication, comorbid 
diagnoses (confirmed by clinical interview/clinician assessment), content of the active 
treatment and control conditions, treatment dose (operationalized as the number of therapy 
sessions and therapy hours provided), percentage of responders, number of patients who 
dropped out of treatment during the treatment phase, and other clinical and methodological 
items objectively used to calculate the quality score of each study (see below). 
 
Risk of bias in individual studies 
The Cochrane Collaboration‟s Tool for Assessing Risk of Bias (Higgins et al., 2011) 
was used to explore possible bias in the individual studies. Studies were assessed across five 
domains: adequate sequence generation, allocation concealment, outcome assessment 
blinding, management of incomplete outcome data and selective reporting. Each study was 
scored using a three-item scale (low, high, or uncertain risk of bias).  
 
Summary Measures 
Effect size of the difference in severity decrease between groups (Cohen‟s delta, i.e. 
the standardized difference in mean decrease) was directly retrieved from the papers 
(Enander et al., In press; Mataix-Cols., 2015; Veale et al., 2014; Wilhelm et al., 2014) or 
derived from the reported statistics (Rabiei, Mulkens, Kalantari, Molavi, & Bahrami, 2012). 
Two other papers (Rosen, Reiter, & Orosan, 1995; Veale et al., 1996) reported the pre- and 
post-treatment means and variances but not the pre-post correlation, which is needed to 
calculate Cohen‟s delta. Rather than estimating a single constant correlation coefficient, the 
pre-post correlation coefficients were meta-analyzed using the MetaNSUE approach (Radua 
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et al., 2015), which yields multiple imputations of the (Fisher-transformed) unknown 
correlation coefficients according to the distribution parameters estimated from all other 
studies. Each set of imputed correlation coefficients was then used to create a set of imputed 
effect sizes. One study (Rosen et al., 1995) reported both the BDD-YBOCS and the BDDE; 
before the final analysis, the separate effect-sizes resulting from both measurements were 
combined into a single one (Rubia et al., 2014). 
  
Synthesis of results 
All effect sizes were corrected for small sample size (Hedges & Olkin, 1985) and 
separately meta-analyzed in each set of imputations using random-effects (in case of main 
analyses) or mixed-effects (in case of meta-regressions) models, which take both intra-study 
and between-study variability into account. The latter, also called “heterogeneity,” was 
estimated with the optimal restricted maximum likelihood (REML) technique (Viechtbauer, 
2005).  
Consistency of these differences was assessed: a) estimating the percentage of 
variability due to between-study heterogeneity (I
2
) and the probability that this is statistically 
significantly different from 0% (so-called “Q test”, but using an F statistic due to the multiple 
imputations); and b) conducting leave-one-out jack-knife analyses (i.e. iteratively repeating 
the meta-analysis with all studies but one).  
The multiple results originated from the different imputation sets were pooled taking 
imputation variability into account (Radua et al., In press). To allow other researchers easily 
follow our approach, we modified MetaNSUE software to automatically conduct meta-
analysis of effect size based on imputation of correlations coefficients (software available at 
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http://www.metansue.com/; please use “referee” as username and “84bnf023” as password to 
access this website). 
Separate meta-analyses were also conducted for depressive symptoms and for insight 
scores, as well as for follow-up severity, although due to the lower number of studies (five, 
four, and three, respectively), complementary analyses other than the jack-knife iterations 
were not conducted. 
 
Drop-out analysis 
Possible differences in the number of patients who dropped out prematurely from 
treatment were investigated between the two arms. Analyses were then repeated considering 
drop-out patients as non-responders, as follows. First, a meta-analysis of the (logarithm-
transformed) relative risk that a patient dropped out from the CBT group (as compared to the 
control group) was conducted. Second, post-treatment means and variances including drop-
out patients were estimated assuming post-treatment mean and variance in drop-out patients 
to be the same as pre-treatment mean and variance. 
 
Risk of bias across studies 
Funnel plots were used to explore the risk of publication or selective reporting bias 
and the possibility of missing studies. Potential bias was further assessed by meta-regressing 
the effect sizes by their standard errors in order to detect whether studies with larger standard 
errors (due to e.g. small sample sizes) report larger effect sizes. 
 
Additional studies (meta-regression) 
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Meta-regressions by year of publication, number of sessions, hours of treatment, 
percentage of females, age, duration of illness, percentage of patients with depressive 
comorbidity, percentage of patients with any comorbidity, percentage of patients with 
delusional symptoms, percentage of patients on SSRI medication, percentage of patients who 
had received a previous cosmetic intervention, and quality/bias score were also conducted, 
correcting for multiple comparisons. 
 
Role of the funding source 
The funder had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. Both first authors had full access to all data in the 
study and had final responsibility for the decision to submit for publication.  
 
Results 
Study selection and study characteristics  
The PRISMA flowchart is shown in Figure 1. Seventeen studies out of a total 211 that 
were initially screened were analyzed for eligibility, leading to a total of seven studies finally 
included in the review, comprising 299 participants with BDD. All studies included adults 
with BDD except for Mataix-Cols et al., (2015) which included an adolescent sample. The 
majority of studies involved individually delivered face-to-face CBT sessions including ERP 
and differing amounts of additional cognitive techniques, compared to no treatment/waitlist 
(Rabiei et al., 2012; Rosen et al., 1995; Veale et al., 1996; Wilhelm et al., 2014), an enhanced 
waitlist (Mataix-Cols et al., 2015), or a credible psychological placebo (Enander et al., 2016; 
Veale et al., 2014). One study compared meta-cognitive therapy based on Wells (2000) with 
a waitlist control and was the only RCT that did not explicitly mention ERP (Rabiei et al., 
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2012), although it included behavioural experiments. One study used a group format (Rosen 
et al., 1995). Another study compared Internet-delivered CBT (including ERP) with Internet-
delivered supportive therapy (Enander et al., 2016) (see Table 1).  
 
Risk of bias within studies 
Table 2 provides data on the risk of bias measured using the Cochrane Collaboration‟s 
Tool for Assessing Risk of Bias.
29
 Of the analyzed studies, four had unclear risk (Rabiei et 
al., 2012; Rosen et al., 1995; Veale et al., 1996; Wilhelm et al., 2014) and three were 
considered to have low risk of bias (Enander et al., 2016; Mataix-Cols et al., 2015; Veale et 
al., 2014). 
 
Results of individual studies and synthesis of results 
The final sample of the meta-analysis consisted of seven RCTs, totaling 299 
individuals.  At post-treatment, improvement on the primary outcome measure was 
significantly higher in patients receiving CBT than in patients on a waitlist or control 
treatment (delta = -1.22, 95% CI = -1.66 to -0.79; p < 0.001; Figure 2). There was moderate 
heterogeneity (I
2 
= 54%), but this did not reach statistical significance (F = 1.3; p = 0.277). 
Jack-knife sensitivity analyses showed that the exclusion of any single study from the 
analysis did not result in any meaningful differences in the overall effect size (Table 3). 
Controlled follow-up data was only available for three studies (Enander et al., 2016; Mataix-
Cols et al., 2015; Rabiei et al., 2012). CBT remained superior to waitlist/control treatment 2 
to 4 months after treatment (delta = -0.89, 95% CI = -1.24 to -0.54; p < 0.001). 
CBT was also associated with significant improvements in comorbid depression 
scores and insight/delusionality, compared to waitlist/control treatments (depression delta [5 
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studies] = -0.49, 95% CI = -0.76 to -0.22; p < 0.001, Figure 3; insight delta [4 studies] = -
0.56, 95% CI = -0.93 to -0.19; p = 0 .003, Figure 4). Jack-knife analysis showed that these 
results were robust, that is, not driven by the effects of any single study (Table 3). Depression 
and insight/delusionality symptoms were not assessed at follow-up given that only two 
studies
30,31
 reported follow-up data.  
  
Drop-out analysis 
No differences in the number of drop-out patients were detected between the CBT and 
waitlist/control groups (relative risk = 1.01, 95% CI = 0.97 – 1.05; p = 0.772), and the results 
of the meta-analyses were similar when considering drop-out patients as non-responders 
(BDD severity: delta = -1.25, 95% CI = -1.84 to -0.65; p<0.001; depression: delta = -0.37, 
95% CI = -0.70 to -0.02; p = 0.036; insight: delta = -0.53, 95% CI = -0.85 to -0.21; p = 
0.001). 
 
Risk of bias across studies 
Inspection of the funnel plot (Figure 5) showed potential reporting bias, though 
regression by standard error was not significant (p = 0.238). 
 
Additional analyses (meta-regression) 
None of the regressors investigated were predictive of changes in BDD severity 
across studies. Too few studies were available for analysis of the secondary outcome 
variables. 
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Discussion 
The main finding of this meta-analysis was that CBT is an efficacious intervention for 
treating the main symptoms of BDD and some of its accompanying features (depressive 
symptoms and insight/delusionality). The meta-analysis also showed that gains are likely to 
be maintained at least in the short term (2-4 months after treatment). Effect sizes were large 
for BDD symptoms and medium for depressive symptoms and insight/delusionality, as would 
be expected from interventions primarily targeting BDD symptoms. The effect sizes were 
comparable to those reported in previous meta-analyses of CBT for OCD, a closely related 
disorder to BDD (Olatunji, Davis, Powers, & Smits, 2013; Öst, Havnen, Hansen, & Kvale, 
2015; Ponniah, Magiati, & Hollon, 2013). Therefore, despite being perceived as difficult to 
treat, BDD patients can achieve meaningful symptom relief when a specialist team delivers 
CBT, at least under the highly controlled conditions of a clinical trial. These findings broadly 
support the recommendations currently included in the NICE guidelines for BDD (National 
Institute for Health and Clinical Excellence, 2006). 
Sensitivity analyses revealed that, despite the substantial methodological 
heterogeneity of the trials conducted to date, which included various types of control groups 
(no treatment/waitlist, active controls), predominant CBT techniques (mainly ERP, cognitive 
therapy-based ERP, meta-cognitive therapy with no explicit ERP), methods of treatment 
delivery (individual, group, Internet-based), and age groups (adults, adolescents), the results 
were remarkably robust; exclusion of any given study at a time did not substantially modify 
the overall effect sizes. This suggests that CBT is probably suitable across a range of 
individuals and robust to the method of delivery, though the evidence for adolescents, group 
CBT, and Internet-based CBT is limited to single trials. 
Employing the widely-used criteria suggested by (Chambless & Hollon, 1998), CBT 
for BDD can be said to be efficacious and possibly specific. Under this framework, 
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efficacious means that two or more independent research groups have found that the 
treatment is superior to no treatment or waitlist, and possibly specific means that CBT is 
probably superior to generic psychological treatment. We conservatively considered that only 
one study to date (Veale et al., 2014) employed a truly credible control treatment. Therefore, 
additional trials are required to test the specificity of CBT for BDD.  
These generally optimistic results need to be tempered by having a closer look at the 
percentage of patients who achieved responder status in these trials. Four of the seven studies 
reported a percentage of responders using an empirically derived cut-off of at least 30% 
change on the BDD-YBOCS (Phillips, Hart, & Menard, 2014); 40% to 54% of patients were 
classified as responders, which is a substantially lower response rate than that typically 
obtained in CBT trials for OCD, where response rates range between 60% and 80%, 
depending on how response is defined (Mataix-Cols et al., 2016; Öst et al., 2015). Many 
participants had post-treatment severity scores in the mild/moderate range, which means that 
they would normally qualify for entry into a BDD clinical trial. It is also our clinical 
impression that many patients with BDD would drop out from treatment in naturalistic 
settings, compared to the „hot pursuit‟ strategies employed in clinical trials of either CBT or 
pharmacotherapy. In a naturalistic 4-year prospective follow-up study of 166 patients with 
BDD, the cumulative probability of being in full remission was 0.20 (Phillips et al., 2013). 
This, coupled with the fact that many BDD patients may refuse or are unable to engage in 
CBT due to low insight, low mood, imminent suicide risk, or other reasons, suggests that 
there is significant room for improvement and that CBT may not be the best or single 
treatment option for all patients with BDD.  
Clearly, there is further room to improve on the existing CBT protocols. For example, 
some patients may require a higher number of sessions. There is some uncontrolled trial data 
to suggest that adding additional sessions (beyond the standard 8-14 sessions employed in 
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previous trials) may lead to further improvement in BDD symptoms (Veale et al., 2014; 
Wilhelm et al., 2014).
 
At present, there is insufficient data to suggest that any particular 
modality of CBT is superior to another. Like in OCD (Öst et al., 2015; Ponniah et al., 2013), 
both exposure-based and cognitive interventions may be comparably efficacious for BDD, 
arguably because these interventions may address the same maintaining factors (e.g., 
avoidance). Dismantling studies may be helpful to determine, for example, if adding 
cognitive techniques (such as metacognitive tools; Rabiei et al., 2012) enhances the efficacy 
of more purely behavioral interventions. As mentioned earlier, further studies comparing 
CBT with credible control treatments are needed to establish the specificity of this treatment. 
Long-term follow-ups of CBT-treated BDD patients are rare (McKay, 1999; Veale, 
Miles, & Anson, 2015).
 
These follow-up studies suggest that many patients maintain their 
gains but longer follow-up studies are needed to confirm this. The optimal strategies, 
pharmacological or psychological, for patients who require additional treatment after a course 
of CBT are unclear. Similarly, sequential trials of SSRI-resistant patients are needed to 
evaluate whether CBT offers additional clinical benefit, as it has been demonstrated in OCD 
(Franklin et al., 2011; Simpson et al., 2008). Unfortunately, no reliable predictors of outcome 
have been identified in BDD to guide clinical decision-making. 
While the results broadly support the NICE guidelines, they do not inform clinicians 
as to which patients should be offered CBT and which should be offered a combination of 
CBT and SRI. Severity alone does not seem a reasonable criterion, since many patients 
included in the CBT trials were in the severe range, and severity did not reliably predict 
outcome. Trials comparing the efficacy and safety of CBT, SSRIs, and their combination are 
needed.  
CBT for adolescents with BDD has only been tested in one small RCT, which 
compared developmentally tailored CBT with an enhanced waitlist control consisting of 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
COGNITIVE-BEHAVIORAL THERAPY FOR BODY DYSMORPHIC DISORDER  17 
 
written psychoeducation materials and weekly phone calls to monitor risk (Mataix-Cols et al., 
2015).
 
Since approximately 70% of patients report symptom onset during adolescence 
(Bjornsson et al., 2013), further trials are warranted in this age group, preferably in the 
incipient phases of the disorder, with the aim of preventing school failure, suicide risk, and 
chronicity. Unfortunately, the disorder often goes undetected in young people, as the 
symptoms of BDD may be mistakenly interpreted as normal developmental concerns (i.e., 
most teenagers worry about their appearance to some extent). More must be done to improve 
early detection and diagnosis of BDD in young people, particularly boys (Mataix-Cols et al., 
2015). 
The development and evaluation of Internet-based interventions for BDD is an 
emerging area that should be explored further. Data from a relatively large RCT (Enander et 
al., 2016) suggest that this can be a highly acceptable, safe, and efficacious way to reach a 
large majority of patients previously unable to access CBT. However, this may only be an 
option for less severe patients who have reasonably intact insight and are therefore motivated 
for treatment. Internet-based CBT may particularly useful in a stepped-care model, where 
mild to moderate cases could be offered the treatment by general practitioners, thus freeing 
resources for more severe and complex cases to be treated in specialized settings. Future 
stepped-care trials of Internet-based CBT in non-specialist settings are warranted. There is 
also preliminary evidence to support the efficacy of group-based CBT for BDD (Linde et al., 
2015; Rosen et al., 1995),
 
which has the potential to be cost-effective in specialist settings 
and should be evaluated further.  
This study has several limitations. First, the studies included in the meta-analysis used 
a range of manualized CBT-based treatments with a degree of heterogeneity in the content 
and format of the CBT offered to patients. Similarly, control conditions were also 
heterogeneous, with most studies using a waitlist as a control, but others using a more active 
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control like anxiety management (Veale et al., 2014) or supportive therapy (Enander et al., 
2016). However, despite this heterogeneity, jack-knife analyses indicated no significant 
differences in overall impact relative to the studies included in the meta-analysis, and a key 
common treatment component was ERP in all studies, with one exception (Rabiei et al., 
2012) in which CBT was focused on developing metacognitive skills. Second, the current 
evidence is based on seven RCTs worldwide, including fewer than 300 patients, and 
conducted primarily in specialist clinics. This may potentially limit the generalizability of the 
results to other settings and to other populations systematically excluded form clinical trials, 
such as those with certain comorbididities (e.g., substance use disorders) or acute suicidal 
behavior. Results on secondary outcomes, namely depressive symptoms and 
insight/delusionality, should especially be interpreted with caution as they were based on 
reports in five and four studies, respectively. Given the relatively small sample, future meta-
analyses of individual participant data may be helpful to further increase power and better 
control for potential confounds (Stewart et al., 2015). Finally, several studies failed to report 
on the ethnic background of their participants; over 80% of patients included in the trials that 
reported this information were from White backgrounds and, thus, it is unclear whether CBT 
is equally acceptable and efficacious in patients from ethnic minorities.   
 
Conclusions  
CBT is an efficacious treatment for BDD symptoms and associated features, but there 
is substantial room for improvement. The specificity and long-term effects of CBT in both 
adults and children/adolescents with BDD require further evaluation using credible control 
conditions. Additional trials comparing CBT with pharmacological therapies, as well as their 
combination, are warranted. Tele-care options, such as Internet-based CBT, hold great 
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promise to increase access to evidence-based treatment for a majority of patients who need it, 
and should be evaluated further.   
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Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses Flowchart 
  
Records identified through 
database searching  
(n = 248)   
Additional records identified 
through other sources  
(n =1)  
Records after duplicates removed 
(n = 211)   
Records screened 
(n = 211)   
Records excluded  
n = 192 
  
n = 75, BDD is not the main diagnosis 
n = 60, review studies 
n = 29, treatments other than CBT (e.g., 
medication, surgery, dermatology) 
n = 21, descriptive, non-interventional  
studies 
n = 3, psychometric studies 
n = 2, animal studies 
n = 1, case series 
n = 1, comment on article 
Studies included in quantitative 
synthesis  
(meta-analysis) 
(n =7)  
Studies included in qualitative 
synthesis  
(n = 7) 
Full-text articles assessed for 
eligibility  
(n = 19) 
Records excluded 
n = 12 
n = 5, open trial 
n = 3, naturalistic study 
n = 1, no formal diagnosis of BDD 
n = 2, conference abstract already published as 
journal paper 
n = 1, RCT with no active CBT phase reported 
(maintenance program) 
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Figure 2: Forest Plot of Primary Outcome Variable: Effect of Cognitive-Behavior Therapy 
on Symptoms of Body Dysmorphic Disorder. 
 
 
 
Footnote: Studies providing sufficient data to derive the exact effect size of the changes in 
the Body Dysmorphic Disorder Examination (BDDE) and the Yale-Brown Obsessive 
Compulsive Scale for Body Dysmorphic Disorder (BDD-YBOCS) are colored black, 
whereas studies with missing data, in which the effect size had to be imputed, are colored 
gray (see MetaNSUE approach in the text). Note that Veale 1996 appears twice: the upper 
row refers to the BDD-YBOCS score whereas the lower row refers to the BDDE score. 
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Figure 3: Forest Plot of Secondary Outcome Variable: Effect of Cognitive-Behavior Therapy 
on Symptoms of Depression. 
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Figure 4: Forest Plot of Secondary Outcome Variable: Effect of Cognitive-Behavior Therapy 
on Insight/Delusionality. 
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Figure 5: Funnel Plot for Primary Outcome Variable: Body Dysmorphic Disorder Severity. 
 
 
 
Footnote: Studies providing enough data to derive the exact effect size of the changes in the 
Body Dysmorphic Disorder Examination (BDDE) and the Yale-Brown Obsessive 
Compulsive Scale for Body Dysmorphic Disorder (BDD-YBOCS) are colored black, 
whereas studies with missing data, in which the effect size had to be imputed, are colored 
gray (see MetaNSUE approach in the text). For each of the latter studies, the light gray 
shadow area shows the interval containing 95% of the imputed effect sizes, whereas the dark 
gray central point shows the mean. 
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Table 1: Characteristics of Studies Included in the Systematic Review. 
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Table 2:  Indicators of Study Quality based on the Cochrane Collaboration’s Tool for 
Assessing Risk of Bias (Higgins & Green, 2011). 
Study 
(chronological 
order) 
Adequate 
sequence 
generation 
Allocation 
concealment 
Blinding 
(outcome 
assessment) 
Incomplete 
outcome 
data 
addressed 
Free of 
selective 
reporting 
Overall 
risk of 
bias 
Rosen et al., 
1995 
Uncertain Uncertain Uncertain Low Low Unclear 
Veale et al., 
1996 
Uncertain Uncertain Uncertain Uncertain Low Unclear 
Rabiei et al., 
2012 
Uncertain Uncertain Uncertain Low Low Unclear 
Veale et al., 
2014 
Low Low Low Low Low Low 
Wilhelm et al., 
2014 
Low Uncertain Low Low Low Unclear 
Mataix-Cols et 
al., 2015 
Low Low Low Low Low Low 
Enander et al., 
2016 
Low Low Low Low Low Low 
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Table 3: Results of the leave-one-out jack-knife analysis for the primary and secondary 
outcomes. 
Discarded study Delta 
95% Confidence 
Interval 
p value 
    
BDD severity     
Rosen 1995 -1.01 -1.28 to -0.75 <0.001 
Veale 1996 (BDD-YBOCS) -1.19 -1.63 to -0.76 <0.001 
Veale 1996 (BDDE) -1.24 -1.68 to -0.80 <0.001 
Rabiei 2012 -1.14 -1.56 to -0.73 <0.001 
Wilhelm 2014 -1.35 -1.85 to -0.84 <0.001 
Veale 2014 -1.25 -1.73 to -0.77 <0.001 
Mataix-Cols 2015 -1.27 -1.80 to -0.75 <0.001 
Enander, in press -1.32 -1.87 to -0.77 <0.001 
    
BDD severity after follow-up   
Rabiei 2012 -0.88 -1.25 to -0.51 <0.001 
Mataix-Cols 2015 -0.90 -1.32 to -0.49 <0.001 
Enander, in press -0.91 -1.51 to -0.32 0.003 
    
Depressive symptoms  
Veale 1996 -0.44 -0.72 to -0.16 0.002 
Wilhelm 2014 -0.55 -0.84 to -0.26 <0.001 
Veale 2014 -0.52 -0.82 to -0.22 <0.001 
Mataix-Cols 2015 -0.43 -0.72 to -0.15 0.003 
Enander, in press -0.55 -0.93 to -0.17 0.004 
    
Insight/delusionality    
Wilhelm 2014 -0.68 -1.15 to -0.21 0.004 
Veale 2014 -0.53 -1.06 to -0.00 0.050 
Mataix-Cols 2015 -0.42 -0.72 to -0.12 0.006 
Enander, in press -0.69 -1.24 to -0.14 0.014 
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Highlights 
 CBT for BDD is efficacious and associated with large sized symptom improvement 
 Treatment gains are maintained 2-4 months after treatment 
 CBT for BDD improves accompanying features (depression and insight/delusionality) 
 Internet-based CBT may help improve access to evidence-based treatments for BDD 
 Additional trials are required to test the specificity of CBT for BDD 
